Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Current Assets (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Current Assets for 3 consecutive years, with $571.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 8.6% to $571.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $571.5 million through Dec 2025, up 8.6% year-over-year, with the annual reading at $571.5 million for FY2025, 8.6% up from the prior year.
  • Current Assets for Q4 2025 was $571.5 million at Nuvation Bio, down from $577.5 million in the prior quarter.
  • The five-year high for Current Assets was $652.6 million in Q1 2023, with the low at $475.6 million in Q1 2025.
  • Average Current Assets over 3 years is $588.8 million, with a median of $597.6 million recorded in 2024.
  • Peak annual rise in Current Assets hit 8.6% in 2025, while the deepest fall reached 21.79% in 2025.
  • Over 3 years, Current Assets stood at $616.4 million in 2023, then dropped by 14.63% to $526.3 million in 2024, then rose by 8.6% to $571.5 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $571.5 million, $577.5 million, and $623.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.